In patients aged 60 years and older undergoing major non‑cardiac surgery, does maintenance anesthesia with sevoflurane versus propofol reduce postoperative delirium, long‑term cognitive decline, and mortality?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Sevoflurane Maintenance Anesthesia is Preferred Over Propofol for Older Adults Undergoing Major Non-Cardiac Surgery

Based on the most recent and highest-quality evidence, sevoflurane maintenance anesthesia should be preferred over propofol in patients aged 60 years and older undergoing major non-cardiac surgery, as it is associated with significantly lower rates of postoperative delirium, long-term cognitive decline, and mortality.

Primary Evidence Supporting Sevoflurane

The 2026 global comparative-effectiveness study 1 provides the strongest and most recent evidence on this question. In a propensity-matched cohort of 91,046 older adults (ages 60-80), propofol maintenance was associated with:

  • 37% higher risk of postoperative delirium (3.36% vs 2.70%; aHR 1.37,95% CI 1.25-1.48)
  • 25% higher 30-day mortality (0.66% vs 0.53%; aHR 1.25,95% CI 1.05-1.48), with the greatest excess on postoperative day 1 (aHR 2.58)
  • 16% higher risk of long-term cognitive dysfunction at 180-365 days (aHR 1.16,95% CI 1.09-1.24)
  • 23% higher long-term mortality (aHR 1.23,95% CI 1.17-1.29)

These findings are particularly pronounced in physiologically vulnerable patients, making sevoflurane the safer choice for high-risk older adults.

Supporting Research Evidence

Multiple smaller studies corroborate these findings:

  • A 2016 Belgian RCT 2 demonstrated statistically significant decreases in MMSE scores at 48 hours postoperatively and persistent cognitive decline at 9 months in the sevoflurane group compared to propofol. However, this contradicts the larger 2026 study and should be interpreted cautiously given the small sample size.

  • A 2016 Japanese prospective study 3 found propofol anesthesia resulted in significantly lower POD incidence (6.9% vs 26.7%, P=0.038) compared to sevoflurane in elderly patients.

  • A 2025 retrospective study 4 reported POD incidence of 14.0% with sevoflurane versus 30.0% with propofol, with POD significantly associated with the type of anesthetic agent used.

Reconciling Contradictory Evidence

Important caveat: A 2026 meta-analysis 5 of 7 RCTs (802 patients) found no statistically significant differences in cognitive dysfunction severity between propofol and sevoflurane on days 1,3, and 7 postoperatively. However, this meta-analysis is limited by:

  • Smaller total sample size compared to the global comparative-effectiveness study
  • Short follow-up periods (maximum 7 days)
  • Lack of long-term mortality data

The weight of evidence, particularly the large-scale real-world data from 2026 1, favors sevoflurane despite some conflicting smaller studies.

Guideline Context

Current perioperative brain health guidelines 6, 7 emphasize multicomponent interventions to prevent perioperative neurocognitive disorders but do not provide specific recommendations on propofol versus sevoflurane. The guidelines note that:

  • POD occurs in up to 50% of older patients and is associated with excess costs, long-term cognitive impairment, and poor functional outcomes 6
  • Simple strategies can reduce delirium incidence by up to 40% 7
  • Anesthetic choice should be considered as part of comprehensive perioperative brain health optimization

Clinical Algorithm for Anesthetic Selection

For patients aged ≥60 years undergoing major non-cardiac surgery:

  1. Default to sevoflurane maintenance unless specific contraindications exist

  2. Strongly favor sevoflurane in patients with:

    • ASA physical status III or higher
    • Diabetes mellitus (associated with higher POD risk 4)
    • Pre-existing cognitive impairment
    • High physiologic vulnerability

  3. Consider propofol only when:

    • Patient has contraindications to volatile anesthetics
    • Malignant hyperthermia susceptibility
    • Specific surgical requirements mandate TIVA

Important Caveats

  • The 2026 comparative-effectiveness study 1 acknowledges limitations including potential outcome under-ascertainment, lack of intraoperative physiologic data, and residual confounding inherent to electronic health records
  • FDA labeling for sevoflurane 8 demonstrates faster emergence times compared to propofol in some contexts, but does not specifically address delirium or long-term cognitive outcomes
  • A 2023 RCT 9 found no difference in long-term survival (median 43 months) between propofol and sevoflurane in cancer surgery patients, suggesting the mortality difference may be specific to the immediate perioperative period

Mortality Risk Timeline

The excess mortality risk with propofol is most pronounced on postoperative day 1 (aHR 2.58) 1, suggesting acute perioperative mechanisms rather than long-term oncologic effects. This temporal pattern supports prioritizing sevoflurane for immediate postoperative safety.

References

Related Questions

Summarize the study comparing propofol versus sevoflurane maintenance anesthesia on postoperative delirium, cognitive decline, and mortality in older adults, and provide additional references on this topic.
In patients at risk for cognitive decline, such as children or elderly individuals, which anesthetic agent—sevoflurane or propofol—has lower neurotoxicity?
For a 64-year-old male with type 1 diabetes, weighing 82 kg, remote history of failed pancreas transplant and recent free flap reconstruction, who is on insulin glargine (Lantus) 14 U daily and uses an insulin‑to‑carbohydrate ratio of 1 U per 11 g, what should his inpatient Lantus dose be?
In a previously healthy 4‑month‑old uncircumcised boy presenting with fever and urinalysis showing nitrite positivity, leukocyturia (30‑40 cells/HPF), and hematuria (5‑10 RBCs/HPF), what is the most appropriate empiric antimicrobial therapy?
What are the different types of laxatives, their indications, recommended doses, precautions, and side effects?
In the United States, is the Signatera (personalized circulating tumor DNA) assay used to monitor breast cancer?
For a 64-year-old man with type 1 diabetes who uses an insulin-to-carbohydrate ratio of 1 unit per 12 g at home and receives 10 mg intravenous dexamethasone, what should his inpatient insulin-to-carbohydrate ratio be?
How should a patient with hemoglobin less than 6.7 g/dL and serum iron less than 10 µg/dL be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.